In vitro interactions of antifungal agents against clinical isolates of Fusarium spp.

被引:41
|
作者
Cordoba, Susana [1 ]
Rodero, Laura [2 ]
Vivot, Walter [1 ]
Abrantes, Ruben [1 ]
Davel, Graciela [1 ]
Vitale, Roxana G. [1 ,3 ,4 ]
机构
[1] ANLIS Dr CG Malbran, INEI, Dept Micol, Buenos Aires, DF, Argentina
[2] Univ Catol, Fac Ciencias Med, Buenos Aires, DF, Argentina
[3] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina
[4] Centraalbureau Voor Schimmelcultures, Utrecht, Netherlands
关键词
Fusarium spp; antifungal susceptibility; antifungal interactions;
D O I
10.1016/j.ijantimicag.2007.09.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro activities of amphotericin B (AMB), itraconazole (ITC), voriconazole (VCZ) and terbinafine (TBF) alone and in the combinations AMB + VCZ, TBF + ITC and TBF + VCZ were evaluated against 29 clinical isolates of Fusarium spp. (15 Fusarium solani, 7 Fusarium oxysporum, 2 Fusarium decemcellulare, 2 Fusarium dimerum and 3 other Fusarium spp.). Minimum inhibitory concentrations were determined using the method of the Clinical and Laboratory Standards Institute and the interaction activity was calculated using the fractional inhibitory concentration index. The four antifungal drugs tested alone showed very limited activity against most of the isolates. In contrast., the combination TBF + VCZ showed synergy for 21 isolates. The combination AMB + VCZ showed synergism for only five strains. No interaction or antagonism was observed among the remaining strains. TBF + ITC showed no interaction for 18 strains. The in vitro antifungal activity of the drugs alone and in combination varied for different species. These results corroborate previous in vitro studies in which the combination TBF + VCZ showed synergy against Fusarium spp., although further studies are needed to elucidate its potential usefulness for therapy. (C) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:171 / 174
页数:4
相关论文
共 50 条
  • [21] In vitro antifungal susceptibility of clinical isolates of Candida spp. from hospitalized patients
    de Resende, JCP
    de Resende, MA
    MYCOSES, 1999, 42 (11-12) : 641 - 644
  • [22] In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization
    Serena, C
    Ortoneda, M
    Capilla, J
    Pastor, FJ
    Sutton, DA
    Rinaldi, MG
    Guarro, J
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) : 3161 - 3164
  • [23] In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp.
    Kamysz, E.
    Simonetti, O.
    Cirioni, O.
    Arzeni, D.
    Ganzetti, G.
    Campanati, A.
    Giacometti, A.
    Gabrielli, E.
    Silvestri, C.
    Kamysz, W.
    Offidani, A.
    Barchiesi, F.
    PEPTIDES, 2011, 32 (01) : 99 - 103
  • [24] Selected Essential Oils as Antifungal Agents Against Antibiotic-Resistant Candida spp.: In Vitro Study on Clinical and Food-Borne Isolates
    Rajkowska, Katarzyna
    Kunicka-Styczynska, Alina
    Maroszynska, Marta
    MICROBIAL DRUG RESISTANCE, 2017, 23 (01) : 18 - +
  • [25] Antifungal Activities of Chaetomium spp. against Fusarium Wilt of Tea
    Nguyen Huu Phong
    Pongnak, Wattanachai
    Soytong, Kasem
    PLANT PROTECTION SCIENCE, 2016, 52 (01) : 10 - 17
  • [26] Antifungal activity of melanin in clinical isolates of Candida spp.
    Fuentes, Marso
    Hernandez, Romane
    Gordillo, Diego
    Amaro, Jose
    Falconer, Mary A.
    Alburquenque, Claudio
    Tapia, Cecilia V.
    REVISTA CHILENA DE INFECTOLOGIA, 2014, 31 (01): : 28 - 33
  • [27] Susceptibility of Candida spp. clinical isolates to antifungal drugs
    Tyski, S.
    Staniszewska, M.
    Rozbicka, B.
    Rajnisz, A.
    Bocian, E.
    Wasinska, E.
    Kurzatkowski, W.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S566 - S566
  • [28] Distribution of invasive isolates of Candida spp. and in vitro susceptibility to antifungal agents: multicenter study in Russia
    Klyasova, G.
    Gracheva, A.
    Maschan, M.
    Molchanova, I.
    Chernenkaya, T.
    Vereshagina, S.
    Zvezdkina, N.
    Kutsevalova, O.
    Khoreva, O.
    Kraynova, L.
    Shushurina, S.
    Popov, D.
    Khokhlyavina, R.
    Okhmat, V.
    MYCOSES, 2013, 56 : 61 - 61
  • [29] In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
    Pfaller, MA
    Messer, SA
    Hollis, RJ
    Jones, RN
    Diekema, DJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) : 1723 - 1727
  • [30] Antifungal activity of low molecular weight chitosan against clinical isolates of Candida spp.
    Alburquenque, Claudio
    Bucarey, Sergio A.
    Neira-Carrillo, Andronico
    Urzua, Blanca
    Hermosilla, German
    Tapia, Cecilia V.
    MEDICAL MYCOLOGY, 2010, 48 (08) : 1018 - 1023